Au@109Pd core–shell nanoparticles conjugated to panitumumab for the combined β−—Auger electron therapy of triple-negative breast cancer

Experimental data collected for the preparation of the manuscript "Au@109Pd Core–Shell Nanoparticles Conjugated to Panitumumab for the Combined β−—Auger Electron Therapy of Triple-Negative Breast Cancer".In our current study, we used 109Pd (T1/2 = 13.7 h) in the form of a 109Pd/109mAg in vivo generator as a source of β− particles and Auger electrons in targeted radionuclide therapy for TNBC. Obtained Au@109Pd-PEG-panitumumab nanoparticles were bound, internalized, and partially routed to the nucleus in MDA-MB-231 human breast cancer cells overexpressing EGFR receptors. We have found that Au@109Pd-PEG-panitumumab nanoparticles show potential as a therapeutic agent for combined β−–Auger electron targeted radionuclide therapy of TNBC. Please consult the Readme.txt file for additional information.